Delivery Order SPE2DB25D3003-SPE2DB25FPWVR
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $3,578.79 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count unit dose) on September 9, 2025, with completion expected by September 10, 2025. This non-competitive, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The order will be...
- The Defense Logistics Agency awarded a $50,518.58 firm fixed-price delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on June 20, 2025, with an ultimate completion date of June 23, 2025. This non-set-aside competitive award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The delivery will be performed at...
- The Defense Logistics Agency awarded a delivery order valued at $74,493.95 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (quantity: 30s) on August 8, 2025, with completion targeted for August 11, 2025. This competitively awarded, non-set-aside contract employs firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion pharmaceutical supply vehicle extending...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 45 MG tablets (28-count unit dose packaging) on August 8, 2025, with an ultimate completion date of August 11, 2025. This competitively awarded, firm fixed-price delivery order has a ceiling value of $11,665.94 and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 2, 2025, for RINVOQ ER 15 mg tablets (30-count units) with a ceiling value of $5,399.73. This is a firm fixed price delivery order with no set-aside designation, executed as a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The product will be delivered to AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $42,368.91 to AmerisourceBergen Drug Corp for RINVOQ ER 30 MG tablets (30-count units) on July 23, 2025, with an ultimate completion date of July 24, 2025. This firm fixed price, non-set-aside contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, valued at $999,999,999.00 and extending through December 2026. The place of...
- The Defense Logistics Agency awarded a $25,189.80 delivery order to AmerisourceBergen Drug Corp on September 2, 2025, for the supply of RINVOQ ER 15 mg tablets in quantities of 30 units. This competitively awarded, firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The contract carries no set-aside designation and...
- The Defense Logistics Agency awarded a $29,485.37 delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-unit package) on July 30, 2025, with a completion date of July 31, 2025. This firm fixed-price delivery order represents a competitively awarded, non-set-aside contract with performance in Conshohocken, Pennsylvania. RINVOQ (upadacitinib) is a JAK inhibitor used to treat rheumatoid arthritis and other inflammatory conditions, reflecting the Defense Logistics Agency's...
- The Defense Logistics Agency awarded a $18,669.96 firm fixed-price delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) on July 23, 2025, with an ultimate completion date of July 24, 2025. This non-set-aside competitive award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The place of performance is...
- The Defense Logistics Agency awarded a $6,562.49 firm fixed-price delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) on April 22, 2025, with an ultimate completion date of April 23, 2025. This non-set-aside contract represents a child delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The pharmaceutical supply will...
- SPE2DB25D3003Indefinite Delivery Contract
- SPE2DB25D3003-SPE2DB25FPWVRDelivery Order
The Defense Logistics Agency awarded a $70,075.90 delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on July 25, 2025, with an ultimate completion date of July 28, 2025. This competitively awarded, firm fixed-price contract represents a child delivery order issued under AmerisourceBergen's broader Indefinite Delivery Contract vehicle with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The contract carries no set-aside designation and will be fulfilled from the contractor's Conshohocken, Pennsylvania facility. RINVOQ (upadacitinib) is a Janus kinase inhibitor used for treating rheumatoid arthritis and other inflammatory conditions, supporting the Defense Health Agency's pharmaceutical supply requirements for military healthcare systems. AmerisourceBergen, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical vendor for federal medical procurement through its comprehensive IDC with DLA, which enables the company to supply a broad range of brand-name and generic medications, vaccines, and medical supplies to support military healthcare programs globally. This delivery order exemplifies the contractor's ongoing role in fulfilling specialized pharmaceutical needs across the federal government's healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $70.1k | 7/25/25 |